Form 4 for STLN Starling Oncology, Inc.
Accepted 2023-03-21 00:00:00 ET · period of report 2023-03-17 · accession 0001628280-23-008825 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-21 | 2023-03-17 | STLN | Hively Brad | CEO, Dir | A - Grant | $0.00 | +168.5K | 724.2K | +30% | $0 |
| D | 2023-03-21 | 2023-03-17 | STLN | Hively Brad | CEO, Dir | A - Grant | $0.00 | +421.3K | 421.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2023-03-17 | A | A | 168,512 | $0.00 | 724,182 | D | — | — | (F1) Represents RSUs with 1/4th of the RSUs vesting on the anniversary of March 17, 2023 (the Vesting Commencement Date), with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. |
| 2 | Derivative | Non-Qualified Stock Option (right to buy) | 2023-03-17 | A | A | 421,280 | $0.00 | 421,280 | D | $0.48 · — to 2033-03-17 | 421,280 Common stock | (F2) The stock options vest as to 1/4th of the options granted on the first anniversary of the Vesting Commencement Date, with the remaining options vesting in four equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. |